Guanfacine Monotherapy for ADHD/ASD Comorbid with Tourette Syndrome: a Case Report

Overview

Journal Ann Gen Psychiatry

Publisher Biomed Central

Specialty Psychiatry

Date 2019 Mar 23

PMID 30899317

Citations 4

Authors

Kosuke Okazaki

Kazuhiko Yamamuro

Junzo Iida

Toshifumi Kishimoto

Affiliations

Soon will be listed here.

Abstract

Background: Patients with attention deficit/hyperactivity disorder (ADHD) often experience comorbid conditions, such as autism spectrum disorder (ASD) and Tourette syndrome (TS). Although pharmacotherapies are effective for treating ADHD, they are likely to elicit a variety of adverse effects. It is, thus, important to select an effective and well-tolerated pharmacotherapeutic treatment for patients with ADHD/ASD comorbid with TS.

Case Presentation: We report the case of a 10-year-old boy with ADHD/ASD comorbid with TS who was treated with guanfacine (GUAN). He experienced several side effects of atomoxetine (ATX) and methylphenidate (MPH) before being treated with GUAN. In the presented case, symptoms of ADHD as well as tic symptoms were improved by treatment with GUAN.

Conclusion: GUAN might be effective and well tolerated in the treatment of patients with ADHD/ASD comorbid with TS who experience side effects of ATX and MPH.

Citing Articles

Therapeutic Approaches for ADHD by Developmental Stage and Clinical Presentation.

Galvez-Contreras A, Cruz I, Beltran-Navarro B, Gonzalez-Castaneda R, Gonzalez-Perez O Int J Environ Res Public Health. 2022; 19(19).

PMID: 36232180 PMC: 9566361. DOI: 10.3390/ijerph191912880.

Norepinephrine and dopamine contribute to distinct repetitive behaviors induced by novel odorant stress in male and female mice.

Lustberg D, Liu J, Iannitelli A, Vanderhoof S, Liles L, McCann K Horm Behav. 2022; 144:105205.

PMID: 35660247 PMC: 10216880. DOI: 10.1016/j.yhbeh.2022.105205.

Ways to Address Perinatal Mast Cell Activation and Focal Brain Inflammation, including Response to SARS-CoV-2, in Autism Spectrum Disorder.

Theoharides T J Pers Med. 2021; 11(9).

PMID: 34575637 PMC: 8465360. DOI: 10.3390/jpm11090860.

Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review.

Tsujii N, Usami M, Naya N, Tsuji T, Mishima H, Horie J Neurol Ther. 2021; 10(2):499-522.

PMID: 34089145 PMC: 8571469. DOI: 10.1007/s40120-021-00249-0.

References

Scahill L . Epidemiology of ADHD in school-age children. Child Adolesc Psychiatr Clin N Am. 2000; 9(3):541-55, vii. View

Scahill L, Chappell P, Kim Y, Schultz R, Katsovich L, Shepherd E . A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001; 158(7):1067-74. DOI: 10.1176/appi.ajp.158.7.1067. View

Devoto P, Flore G, Pani L, Gessa G . Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol Psychiatry. 2001; 6(6):657-64. DOI: 10.1038/sj.mp.4000904. View

Franowicz J, Kessler L, Borja C, Kobilka B, Limbird L, Arnsten A . Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J Neurosci. 2002; 22(19):8771-7. PMC: 6757781. View

Bymaster F, Katner J, Nelson D, Hemrick-Luecke S, Threlkeld P, Heiligenstein J . Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002; 27(5):699-711. DOI: 10.1016/S0893-133X(02)00346-9. View

Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J . European clinical guidelines for hyperkinetic disorder -- first upgrade. Eur Child Adolesc Psychiatry. 2004; 13 Suppl 1:I7-30. DOI: 10.1007/s00787-004-1002-x. View

Yoshida Y, Uchiyama T . The clinical necessity for assessing Attention Deficit/Hyperactivity Disorder (AD/HD) symptoms in children with high-functioning Pervasive Developmental Disorder (PDD). Eur Child Adolesc Psychiatry. 2004; 13(5):307-14. DOI: 10.1007/s00787-004-0391-1. View

Sonuga-Barke E . Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry. 2005; 57(11):1231-8. DOI: 10.1016/j.biopsych.2004.09.008. View

Biederman J, Faraone S . Attention-deficit hyperactivity disorder. Lancet. 2005; 366(9481):237-48. DOI: 10.1016/S0140-6736(05)66915-2. View

10.

. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005; 62(11):1266-74. DOI: 10.1001/archpsyc.62.11.1266. View

11.

Albin R . Neurobiology of basal ganglia and Tourette syndrome: striatal and dopamine function. Adv Neurol. 2006; 99:99-106. View

12.

Dooley J . Tic disorders in childhood. Semin Pediatr Neurol. 2006; 13(4):231-42. DOI: 10.1016/j.spen.2006.09.004. View

13.

Wang M, Ramos B, Paspalas C, Shu Y, Simen A, Duque A . Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007; 129(2):397-410. DOI: 10.1016/j.cell.2007.03.015. View

14.

Arnsten A, Scahill L, Findling R . alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol. 2007; 17(4):393-406. DOI: 10.1089/cap.2006.0098. View

15.

Biederman J, Melmed R, Patel A, McBurnett K, Donahue J, Lyne A . Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2009; 13(12):1047-55. DOI: 10.1017/s1092852900017107. View

16.

Gizer I, Ficks C, Waldman I . Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009; 126(1):51-90. DOI: 10.1007/s00439-009-0694-x. View

17.

Wigal S . Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs. 2009; 23 Suppl 1:21-31. DOI: 10.2165/00023210-200923000-00004. View

18.

Bloch M, Panza K, Landeros-Weisenberger A, Leckman J . Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009; 48(9):884-893. PMC: 3943246. DOI: 10.1097/CHI.0b013e3181b26e9f. View

19.

Sallee F . The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder. Postgrad Med. 2010; 122(5):78-87. DOI: 10.3810/pgm.2010.09.2204. View

20.

Volkow N, Wang G, Tomasi D, Kollins S, Wigal T, Newcorn J . Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. J Neurosci. 2012; 32(3):841-9. PMC: 3350870. DOI: 10.1523/JNEUROSCI.4461-11.2012. View